UPDATE: Eliem Therapeutics (ELYM) Reiterated at Buy by Stifel Despite ETX-810 Failure, "Still Like LSR Set-Up, But Stock Now Materially Riskier"
Tweet Send to a Friend
(Updated - April 25, 2022 7:38 AM EDT)
Stifel analyst Paul Matteis reiterated a Buy rating on Eliem Therapeutics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Stifel analyst Paul Matteis reiterated a Buy rating on Eliem Therapeutics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
